Use of carbon monoxide breath test to assess red blood cell lifespan in newly diagnosed multiple myeloma patients

2019 ◽  
Vol 13 (4) ◽  
pp. 046008 ◽  
Author(s):  
Yanfang Wang ◽  
Zhenhao Zhang ◽  
Yan Liu ◽  
Hongmei Jing ◽  
Xiaoyan Ke ◽  
...  
2019 ◽  
Vol 13 (2) ◽  
pp. 026007
Author(s):  
Mei-qing Lei ◽  
Ling-feng Sun ◽  
Xian-sheng Luo ◽  
Xiao-yang Yang ◽  
Feng Yu ◽  
...  

2009 ◽  
Vol 154 (1) ◽  
pp. 15-17 ◽  
Author(s):  
Sheeja M. Krishnan ◽  
Narendra M. Dixit

2021 ◽  
Vol 35 (S1) ◽  
Author(s):  
Anna Pearson ◽  
Todd Schmitt ◽  
Todd Robeck ◽  
Luis Hückstädt ◽  
Michael Tift

2019 ◽  
Vol 19 (10) ◽  
pp. e178
Author(s):  
Sara Aida Jiménez-Julià ◽  
Albert Pérez Montaña ◽  
Sandra Pérez León ◽  
Bernardo López Andrade ◽  
José María Sánchez Raga ◽  
...  

2018 ◽  
Vol 481 ◽  
pp. 34-41 ◽  
Author(s):  
Di Zhou ◽  
Peipei Xu ◽  
Miaoxin Peng ◽  
Xiaoyan Shao ◽  
Miao Wang ◽  
...  

2021 ◽  
Author(s):  
Ying Jiang ◽  
Jiu‐Hong Li ◽  
Jun‐Feng Luo ◽  
Quan‐Sheng Han ◽  
Sheng‐Lang Zhu ◽  
...  

2022 ◽  
Vol 66 (9-10) ◽  
pp. 30-38
Author(s):  
N. M. Krasnova ◽  
S. G. Efremenko ◽  
N. E. Evdokimova ◽  
O. I. Filippova ◽  
Y. V. Chertovskikh ◽  
...  

Background. Individual sensitivity to isoniazid in tuberculosis patients is determined by the presence of N-acetyltransferase 2 (NAT2) enzyme gene allelic variants in genome. Evaluation of quantitative and qualitative alterations in peripheral blood can be used for diagnosis, disease severity estimation, or as a clue for estimation of anti-tuberculosis chemotherapy effectiveness and safety.Aim: Find associations between acetylation type and peripheral red blood cell (RBC) dynamics; determine the effect of NAT2 acetylation rate on the effectiveness and safety of treatment in patients with newly identified pulmonary tuberculosis (TB) residing in the Sakha Republic (Yakutia).Methods. This study included 146 patients with various clinical forms of newly diagnosed pulmonary TB. Oral isoniazid, rifampicin, pyrazinamide, and ethambutol were administered patients. Genotyping was performed via real time PCR.Results. Rapid and intermediate acetylators showed an increase in hemoglobin concentrations and RBC erythrocyte hemoglobin content by the end of chemotherapy (P<0.05). Incidence of anemia was lower in intermediate acetylators, compared to rapid or slow acetylators (P=0.013). Negative correlation was established between absolute RBC count and slow acetylation type (P=0.017). Patients with rapid acetylation type showed increased RBC distribution width indexes RDW-CV and RDW-SD (P<0.05).Conclusions. An adequate therapeutic effect was achieved with standard doses of anti-TB medications in patients with intermediate acetylation type. Rapid and slow acetylators required anti-TB medication dose correction. Genotyping for NAT2 gene in patients with pulmonary TB enables clinicians to choose the optimal dose of anti-TB medications, specifically, isoniazid dose.


Author(s):  
Matthias Schneider ◽  
Niklas Schäfer ◽  
Anna-Laura Potthoff ◽  
Leonie Weinhold ◽  
Lars Eichhorn ◽  
...  

AbstractThe influence of perioperative red blood cell (RBC) transfusion on prognosis of glioblastoma patients continues to be inconclusive. The aim of the present study was to evaluate the association between perioperative blood transfusion (PBT) and overall survival (OS) in patients with newly diagnosed glioblastoma. Between 2013 and 2018, 240 patients with newly diagnosed glioblastoma underwent surgical resection of intracerebral mass lesion at the authors’ institution. PBT was defined as the transfusion of RBC within 5 days from the day of surgery. The impact of PBT on overall survival was assessed using Kaplan–Meier analysis and multivariate regression analysis. Seventeen out of 240 patients (7%) with newly diagnosed glioblastoma received PBT. The overall median number of blood units transfused was 2 (95% CI 1–6). Patients who received PBT achieved a poorer median OS compared to patients without PBT (7 versus 18 months; p < 0.0001). Multivariate analysis identified “age > 65 years” (p < 0.0001, OR 6.4, 95% CI 3.3–12.3), “STR” (p = 0.001, OR 3.2, 95% CI 1.6–6.1), “unmethylated MGMT status” (p < 0.001, OR 3.3, 95% CI 1.7–6.4), and “perioperative RBC transfusion” (p = 0.01, OR 6.0, 95% CI 1.5–23.4) as significantly and independently associated with 1-year mortality. Perioperative RBC transfusion compromises survival in patients with glioblastoma indicating the need to minimize the use of transfusions at the time of surgery. Obeying evidence-based transfusion guidelines provides an opportunity to reduce transfusion rates in this population with a potentially positive effect on survival.


Sign in / Sign up

Export Citation Format

Share Document